CO2020013545A2 - Formulación estable de anticuerpos - Google Patents
Formulación estable de anticuerposInfo
- Publication number
- CO2020013545A2 CO2020013545A2 CONC2020/0013545A CO2020013545A CO2020013545A2 CO 2020013545 A2 CO2020013545 A2 CO 2020013545A2 CO 2020013545 A CO2020013545 A CO 2020013545A CO 2020013545 A2 CO2020013545 A2 CO 2020013545A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibody formulation
- stable antibody
- formulation
- antibody
- formulations
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201841013645 | 2018-04-10 | ||
| PCT/IN2019/050291 WO2019198099A1 (en) | 2018-04-10 | 2019-04-10 | Stable antibody formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020013545A2 true CO2020013545A2 (es) | 2021-01-18 |
Family
ID=68164052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0013545A CO2020013545A2 (es) | 2018-04-10 | 2020-10-28 | Formulación estable de anticuerpos |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12024561B2 (https=) |
| EP (1) | EP3773695A4 (https=) |
| JP (1) | JP2021521168A (https=) |
| CN (1) | CN112243379A (https=) |
| AU (1) | AU2019251452A1 (https=) |
| BR (1) | BR112020020741A2 (https=) |
| CO (1) | CO2020013545A2 (https=) |
| SG (1) | SG11202009872YA (https=) |
| WO (1) | WO2019198099A1 (https=) |
| ZA (1) | ZA202006262B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2358763C2 (ru) * | 2003-02-10 | 2009-06-20 | Элан Фармасьютикалз, Инк. | Композиции иммуноглобулина и способ их получения |
| US20090208492A1 (en) * | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| WO2009141239A1 (en) * | 2008-05-20 | 2009-11-26 | F. Hoffmann-La Roche Ag | A pharmaceutical formulation comprising an antibody against ox40l, uses thereof |
| AR076640A1 (es) * | 2009-03-06 | 2011-06-29 | Genentech Inc | Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura |
| UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| DK3311834T3 (da) * | 2011-05-02 | 2026-04-20 | Millennium Pharmaceuticals Inc | Formulering til anti-alfa4beta7-antistof |
| AU2019251453A1 (en) * | 2018-04-10 | 2020-11-26 | Dr. Reddy’S Laboratories Limited | Stable formulations of therapeutic antibody |
| US12030948B2 (en) * | 2018-04-10 | 2024-07-09 | Dr. Reddy's Laboratories Limited | Antibody formulation |
| US20220267449A1 (en) * | 2019-06-10 | 2022-08-25 | Takeda Pharmaceutical Company Limited | METHODS OF PRODUCING AN ANTI-a4B7 ANTIBODY |
| AU2020290999A1 (en) * | 2019-06-10 | 2022-02-03 | Takeda Pharmaceutical Company Limited | Antibody purification methods and compositions thereof |
-
2019
- 2019-04-10 AU AU2019251452A patent/AU2019251452A1/en not_active Abandoned
- 2019-04-10 BR BR112020020741-1A patent/BR112020020741A2/pt not_active IP Right Cessation
- 2019-04-10 US US17/045,336 patent/US12024561B2/en active Active
- 2019-04-10 WO PCT/IN2019/050291 patent/WO2019198099A1/en not_active Ceased
- 2019-04-10 SG SG11202009872YA patent/SG11202009872YA/en unknown
- 2019-04-10 CN CN201980038032.1A patent/CN112243379A/zh active Pending
- 2019-04-10 EP EP19785443.3A patent/EP3773695A4/en active Pending
- 2019-04-10 JP JP2020555449A patent/JP2021521168A/ja active Pending
-
2020
- 2020-10-08 ZA ZA2020/06262A patent/ZA202006262B/en unknown
- 2020-10-28 CO CONC2020/0013545A patent/CO2020013545A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202009872YA (en) | 2020-11-27 |
| EP3773695A4 (en) | 2021-12-22 |
| EP3773695A1 (en) | 2021-02-17 |
| AU2019251452A1 (en) | 2020-11-26 |
| JP2021521168A (ja) | 2021-08-26 |
| ZA202006262B (en) | 2023-01-25 |
| BR112020020741A2 (pt) | 2021-01-19 |
| US12024561B2 (en) | 2024-07-02 |
| AU2019251452A2 (en) | 2020-12-03 |
| WO2019198099A1 (en) | 2019-10-17 |
| CN112243379A (zh) | 2021-01-19 |
| US20210253714A1 (en) | 2021-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020013571A2 (es) | Formulaciones estables de anticuerpos terapéuticos | |
| CO2019011021A2 (es) | Formulacion estable de anticuerpos | |
| CL2020002012A1 (es) | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. (divisional solicitud 201903032) | |
| MX2025010757A (es) | Formulacion farmaceutica de ph bajo | |
| MX2021014863A (es) | Composiciones de proteina anti-vegf y metodos para producir la misma. | |
| MX385109B (es) | Formulaciones de anticuerpos. | |
| CO2020016008A2 (es) | Formulación de proteína de fusión estable | |
| BR112016026811A2 (pt) | formulação de anticorpo | |
| MX2015015152A (es) | Formulaciones de anticuerpos biespecificos anti-il-4/anti-il-13. | |
| CL2017001115A1 (es) | Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf. | |
| CO2022005737A2 (es) | Formulación estable de anticuerpo de integrina | |
| CO2021010697A2 (es) | Formulación de anticuerpos terapéuticos | |
| AR095396A1 (es) | Formulaciones de anticuerpo | |
| WO2018075692A3 (en) | Antibody constructs | |
| AR108631A1 (es) | Formulación de neurotoxinas | |
| CO2020016014A2 (es) | Formulación de proteína de fusión ctla4-ig | |
| MX380569B (es) | Métodos y formulaciones que permiten la modulación de respuestas inmunitarias relacionadas con la administración de un fármaco biofarmacéutico. | |
| CO2020013545A2 (es) | Formulación estable de anticuerpos | |
| MX2021005910A (es) | Formulacion de proteina de alta concentracion. | |
| AR117407A1 (es) | Formulaciones acuosas estables de anticuerpos anti-tau | |
| MX2020004675A (es) | Formulaciones de alcohol de seda. | |
| AR117607A1 (es) | Formulaciones de anticuerpo líquidas de alta concentración | |
| BR112023002984A2 (pt) | Formulações de anticorpo terapêutico | |
| BR112018011590A2 (pt) | formulação cosmética | |
| AR106510A1 (es) | Formulaciones de anticuerpo antifactor d |